A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial evaluates the effects of bicalutamide, compared to no study drug (NSD), on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder cancer. Bicalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Previous studies have suggested that expression of a protein called EGFR on tumor cells is related to bladder cancer disease progression. This trial may help doctors evaluate if bicalutamide has any effect on EGFR expression in patients with non-muscle invasive bladder cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 18 lat i starsi.
- •Podejrzenie raka pęcherza moczowego, który nie wrasta w mięśnie.
- •Nie ma oznak raka górnych dróg moczowych ani przerzutów.
- •Rak pęcherza jest nowy lub nawracał rzadko (maks. 2 epizody w ciągu 18 miesięcy).
- •Pacjenci mogą mieć jeden lub więcej guzów.
- •Ogólny stan zdrowia dobry (nie przeszkadza w codziennych czynnościach).
✗ Disqualifies
- •Osoby poniżej 18. roku życia.
- •Choroby wątroby przekraczające określone normy.
- •Infekcje dróg moczowych wymagające leczenia.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (6)
University of Arizona Cancer Center - Prevention Research Clinic
Tucson, United States
Cedars Sinai Medical Center
Los Angeles, United States
National Cancer Institute Urologic Oncology Branch
Bethesda, United States
University of Rochester
Rochester, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, United States
Trial contact
Juan Chipollini
Juan Chipollini
PRINCIPAL_INVESTIGATOR
Michael A. Ahdoot
Michael A. Ahdoot
PRINCIPAL_INVESTIGATOR
Sandeep Gurram
Sandeep Gurram
PRINCIPAL_INVESTIGATOR
Edward M. Messing
Edward M. Messing
PRINCIPAL_INVESTIGATOR
Debasish Sundi
Debasish Sundi
PRINCIPAL_INVESTIGATOR
Kyle A. Richards
Kyle A. Richards
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.